Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2012

01-01-2012 | Original Article

Different combination schedules of gemcitabine with endostar affect antitumor efficacy

Authors: Xing-Chen Peng, Meng Qiu, Meng Wei, Ben-Xu Tan, Jun Ge, Yu Zhao, Ye Chen, Ke Cheng, Yi Zhou, Yang Wu, Feng-Ming Gong, Qiu Li, Feng Xu, Feng Bi, Ji-Yan Liu

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2012

Login to get access

Abstract

Purpose

Antiangiogenic drugs inhibit tumor growth by decreasing blood supply and causing transient “normalization” of the tumor vasculature, thereby improving the delivery of systemic chemotherapy. A higher dose of antiangiogenic drugs may lead to a more marked decrease in intratumoral blood flow but may concomitantly cause a decrease in delivery of chemotherapeutic agents. The purpose of this study was to define an optimal schedule for the combination of gemcitabine with a recombinant endostatin, endostar.

Methods

We evaluated the antitumor effects with different schedules of gemcitabine combined with or without endostar. The changes of vascular endothelial growth factor (VEGF) levels in tumor extracts and sera after gemcitabine treatment were examined. Endostar was also assessed for its abilities to inhibit the increase in VEGF levels. Apoptotic cells and microvessel density within tumor tissue were also examined.

Results

Endostar administered simultaneously with or following gemcitabine improved the inhibition of tumor growth, compared with gemcitabine alone. VEGF levels decreased immediately after gemcitabine treatment, but increased in the following several days. Endostar administered simultaneously with or following gemcitabine could inhibit the increase in VEGF levels, thereby cause a decreased vessel density and an increased apoptosis in tumor tissue.

Conclusions

Our finding suggested that endostar given simultaneously with or following gemcitabine might be optimal to enhance the antitumor effect.
Literature
1.
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18PubMed
2.
3.
Kirsch M, Schackert G, Black PM (2000) Angiogenesis, metastasis, and endogenous inhibition. J Neurooncol 50:173–180PubMedCrossRef
4.
Tandle A, Blazer DG III, Libutti SK (2004) Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2:22PubMedCrossRef
5.
Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380PubMedCrossRef
6.
Gourley M, Williamson JS (2000) Angiogenesis: new targets for the development of anticancer chemotherapies. Curr Pharm Des 6:417–439PubMedCrossRef
7.
Folkman J, Hanahan D (1991) Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 22:339–347PubMed
8.
Dhanabal M, Ramchandran R, Waterman MJF, Hua LU, Knebelmann B, Segal M, Sukhatme VP (1999) Endostatin induces endothelial cell apoptosis. J Biol Chem 274:11721–11726PubMedCrossRef
9.
Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh L (2002) Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 62:1944–1947PubMed
10.
Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG (2002) Endostatin blocks VEGF-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277:27872–27879PubMedCrossRef
11.
Ding I, Sun JZ, Fenton B, Liu WM, Kimsely P, Okunieff P, Min W (2001) Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res 61:526–531PubMed
12.
Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SLC (2000) Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 97:4802–4807PubMedCrossRef
13.
Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404–407PubMedCrossRef
14.
Herbst RS, Lee AT, Tran HT, Abbruzzese JL (2001) Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 3:131–140PubMedCrossRef
15.
Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886PubMed
16.
Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, Landré J, Pluderi M, Tomei G, Villani R et al (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61:7501–7506PubMed
17.
Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13:3942–3950PubMedCrossRef
18.
Arup B, Mukund S, Steven DO, Károly T, Mary MV, Youcef MR (2008) Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer Drugs. Clin Cancer Res 14:3926–3932CrossRef
19.
Jie M, David JW (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7:3670–3684CrossRef
20.
Ruud PMD, Melissa L, Hanke H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ (2007) Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13:3395–3402CrossRef
21.
Jia H, Kling J (2006) China offers alternative gateway for experimental drugs. Nat Biotechnol 24:117–118PubMedCrossRef
22.
Song HF, Liu XW, Zhang HN, Zhu BZ, Yuan SJ, Liu SY, Tang ZM (2005) Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin 26:124–128PubMedCrossRef
23.
Shi W, Tang Q, Chen X, Cheng P, Jiang P, Jing X, Chen X, Chen P, Wang Y, Wei Y et al (2009) Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J Mol Med 87:493–506PubMedCrossRef
24.
Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY, Wen YJ, Niu T, Xiao F, Lou YY et al (2005) Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology 69:81–87PubMedCrossRef
25.
Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Eng J Med 324:1–8CrossRef
26.
27.
Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G (2002) Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5:237–256PubMedCrossRef
28.
Calatayud S, Warner TD, Mitchell JA (2002) Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs. Br J Cancer 86:1316–1321PubMedCrossRef
29.
Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, Hallahan DE (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413–2419PubMed
30.
Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW et al (1999) Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378PubMed
31.
Taylor AP, Ososrio L, Craig R, Raleigh JA, Ying Z, Goldenberg DM, Blumenthal RD (2002) Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin Cancer Res 8:1213–1222PubMed
32.
Wang J, Lou P, Lesniewski R, Henkin J (2003) Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14:13–19PubMedCrossRef
33.
Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369–3372PubMed
34.
Miyahara Y, Yoshida S, Motoyama S, Tateiwa Y, Hamana S, Maruo T (2004) Effect of cis-diammine dichloroplatinum on vascular endothelial growth factor expression in uterine cervical carcinoma. Eur J Gynaecol Oncol 25:33–39PubMed
35.
Riedel F, Götte K, Goessler U, Sadick H, Hörmann K (2004) Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines. Anticancer Res 24:2179–2183PubMed
36.
Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M (2003) Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2:753–763PubMed
37.
Mills PJ, Parker B, Jones V, Adler KA, Perez CJ, Johnson S, Cohen-Zion M, Marler M, Sadler GR, Dimsdale JE et al (2004) The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin Cancer Res 10:4998–5003PubMedCrossRef
Metadata
Title
Different combination schedules of gemcitabine with endostar affect antitumor efficacy
Authors
Xing-Chen Peng
Meng Qiu
Meng Wei
Ben-Xu Tan
Jun Ge
Yu Zhao
Ye Chen
Ke Cheng
Yi Zhou
Yang Wu
Feng-Ming Gong
Qiu Li
Feng Xu
Feng Bi
Ji-Yan Liu
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-011-1695-8

Other articles of this Issue 1/2012

Cancer Chemotherapy and Pharmacology 1/2012 Go to the issue

Original Article

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

Original Article

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects

Original Article

The marine sponge toxin agelasine B increases the intracellular Ca2+ concentration and induces apoptosis in human breast cancer cells (MCF-7)

Short Communication

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma

Original Article

Hematologic adverse events associated with temozolomide

Original Article

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits